Associated Papers
SH2B3 (Lnk) Mutations in Myeloid Neoplasms: Morphologic Spectrum, Co-Mutation Patterns, and Clinical Correlates.
Tefferi A et al.
American Journal of Hematology, 2025
Characteristics and prognosis of rrDLBCL with TP53 mutations and a high-risk subgroup represented by the co-mutations of DDX3X-TP53.
Gao F et al.
Cancer Medicine, 2023
36971051 (PubMed )
Supplement: CAM4-12-10267-s001.xlsx › Sheet1
PAX6 disease models for aniridia.
Abdolkarimi D et al.
Indian Journal of Ophthalmology, 2022
Actionable Molecular Alterations Are Revealed in Majority of Advanced Non-Small Cell Lung Cancer Patients by Genomic Tumor Profiling at Progression after First Line Treatment.
Frank MS et al.
Cancers, 2021
35008297 (PubMed )
Supplement: cancers-14-00132-s001.zip › Supplementary_Table_S1.xlsx › Overview_ver2
Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing.
Gao F et al.
Frontiers in Genetics, 2021
34925435 (PubMed )
Supplement: DataSheet2.xlsx › Sheet1
The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders.
Maslah N et al.
Leukemia, 2017
LNK mutations and myeloproliferative disorders.
McMullin MF et al.
American Journal of Hematology, 2016
12q24 locus association with type 1 diabetes: SH2B3 or ATXN2?
Auburger G et al.
World Journal of Diabetes, 2014
Role of the adaptor protein LNK in normal and malignant hematopoiesis.
Gery S et al.
Oncogene, 2013
LNK can also be mutated outside PH and SH2 domains in myeloproliferative neoplasms with and without V617FJAK2 mutation.
Hurtado C et al.
Leukemia Research, 2011
[Classification for myeloproliferative neoplasms and function of novel mutations].
Kirito K
[rinsho Ketsueki] the Japanese Journal of Clinical Hematology, 2011
When the Brakes are Lost: LNK Dysfunction in Mice, Men, and Myeloproliferative Neoplasms.
Oh ST
Therapeutic Advances in Hematology, 2011
LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations.
Pardanani A et al.
Leukemia, 2010
LNK mutations in JAK2 mutation-negative erythrocytosis.
Lasho TL et al.
The New England Journal of Medicine, 2010
Select a paper to view details